Products for Research Use Only

Chlorotrianisene-d9

CAT: 0804-HY-B2158S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B2158S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Chlorotrianisene-d9 is the deuterium labeled Chlorotrianisene. Chlorotrianisene is a long-acting non-steroidal estrogen and an orally active estrogen receptor modulator. Chlorotrianisene exhibits antiestrogenic activity. Chlorotrianisene potently inhibits the enzyme COX-1 and inhibits platelet aggregation in whole blood[1][2][3].
CAS Number
1276197-26-2
UNSPSC
12352005
Target
COX; Estrogen Receptor/ERR; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Immunology/Inflammation; Others; Vitamin D Related/Nuclear Receptor
Field of Research
Endocrinology; Cardiovascular Disease
Solubility
10 mM in DMSO
Smiles
Cl/C(C1=CC=C(C=C1)OC([2H])([2H])[2H])=C(C2=CC=C(C=C2)OC([2H])([2H])[2H])\C3=CC=C(C=C3)OC([2H])([2H])[2H]
Molecular Formula
C23H12D9ClO3
Molecular Weight
389.92
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Ruenitz PC, et al. Estrogenic tamoxifen derivatives: categorization of intrinsic estrogenicity in MCF-7 cells. J Steroid Biochem Mol Biol. 1997 Nov-Dec;63 (4-6) :203-9.|[3]Lounkine E, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature. 2012 Jun 10;486 (7403) :361-7.|[4]Kupfer D, et al. Inactivation of the uterine estrogen receptor binding of estradiol during P-450 catalyzed metabolism of chlorotrianisene (TACE) . Speculation that TACE antiestrogenic activity involves covalent binding to the estrogen receptor. FEBS Lett. 1990 Feb 12;261 (1) :59-62.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products